ストックスクリーナーアプリを入手
92.57
1.62%
1.48
前日終値:
$91.09
開ける：
$90.92
24時間の取引高:
17.72M
Relative Volume:
2.77
時価総額：
$115.37B
収益：
$28.30B
当期純損益:
$126.00M
株価収益率:
21.28
EPS:
4.35
ネットキャッシュフロー:
$9.43B
1週間 パフォーマンス:
+0.78%
1か月 パフォーマンス:
+4.45%
6か月 パフォーマンス:
+35.16%
1年 パフォーマンス:
+17.79%
1日の値動き範囲:
$90.71
$93.29
1週間の範囲:
$90.27
$93.59
52週間の値動き範囲:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
92.57 | 115.37B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences, Inc. (NASDAQ:GILD) Position Raised by Principal Financial Group Inc. - MarketBeat
Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold? - Yahoo Finance
Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes - Pharmaceutical Business Review
Gilead invests in Assembly Bio to advance clinical programs - The Pharma Letter
Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis - PMLiVE
Integrase Inhibitors Market Top PlayersGilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC. - openPR
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance
Gilead plans to halt free access to an HIV drug, worrying patient advocates - STAT
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com
(GILD)Analyzing Gilead Sciences's Short Interest - Benzinga
Gilead’s twice-yearly PrEP chosen as breakthrough of the year - Bay Area Reporter, America's highest circulation LGBT newspaper
Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies - Fierce Biotech
Gilead raises Assembly Bio stake to ~30% - MSN
Gilead recruits Terray in AI-driven drug discovery pact - OutSourcing-Pharma.com
Assembly Bio stock rises as Gilead ups stake (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding - MarketWatch
Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead - MarketWatch
Xilio Therapeutics Secures $25M Investment from Gilead - TipRanks
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs - The Manila Times
Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline - StockTitan
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy - Medical Dialogues
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Page 22 | GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001 Trade Ideas — BCBA:GILD - TradingView
Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer - Yahoo Finance
Gilead and Terray Therapeutics collaborate on drug discovery - BioWorld Online
Gilead and Terray enter small molecule drug development deal - World Pharmaceutical Frontiers
Gilead, Terray Therapeutics announce research collaboration - Yahoo Finance
Gilead and Terray link to develop small-molecule therapies - Yahoo Finance
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure - Seeking Alpha
Andrew D. Dickinson Sells 8,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences CFO sells $781,660 in stock - Investing.com
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Gilead's New HIV Drug Aims For Global Impact By 2026 - Finimize
Gilead, Terray to collaborate on small molecule drugs (GILD:NASDAQ) - Seeking Alpha
FDA grants breakthrough status to Gilead's lung cancer drug - Investing.com
Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy - StreetInsider.com
(sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
Gilead inks multi-target deal with Terray Therapeutics - The Pharma Letter
Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact - Fierce Biotech
Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration - MarketWatch
Gilead appoints Dietmar Berger as chief medical officer - PMLiVE
Gilead partners with Terray for AI-driven drug discovery - Investing.com India
AI-discovery partnership with Gilead will help Terray achieve its pipeline goals - FirstWord Pharma
Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - StreetInsider.com
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - Business Wire
B. Riley Wealth Advisors Inc. Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Dec 16 '24 |
Sale |
91.96 |
8,500 |
781,660 |
132,373 |
1.83%
1.48%
大文字化:
|
ボリューム (24 時間):